Considerations for Maintaining Safety in Biobanks during the COVID-19 Pandemic: A Systematic Review

Document Type : Systematic Review

Authors
1 Department of Community Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria
2 1. Department of Community Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria. 2. Department of Community Medicine, University College Hospital, Ibadan, Oyo State, Nigeria
Abstract
Backgrounds: COVID-19 diagnostic testing and research substantially depend on high-quality COVID-19 specimens, for which biobanks are an important repository. This systematic review aimed to highlight the considerations for maintaining safety in biobanks during the COVID-19 pandemic.

Materials & Methods: A systematic review of literature was conducted using the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. The literature search was conducted across Google Scholar, PubMed, and Directory of Open Access Journal because of their high indexation on many journals. Pre-defined search terms were used in the literature search. Overall, 7,184 articles were retrieved, and 2,054 duplicates among them were removed. After screening for eligibility using pre-defined criteria, 12 articles were included in the review.

Findings: Challenges faced by biobanks amid the COVID-19 pandemic include poor handling of COVID-19 specimens, poor sample collection, and sample contamination due to unclarified standard operating procedures. Strategies such as developing a framework for governing and monitoring the export of biological samples should be employed to overcome dangers eminent in the collection of biological samples. Total adherence to standard operating procedures should be ensured to maintain safety in COVID-19 samples collection, handling, and storage modalities. A deficit in material supply should be promptly addressed.

Conclusion: Compliance with issued guidelines should be ensured by the management and staff of COVID-19 biobanks.

Keywords


References
1. World Health Organization. Coronavirus. Available: https://www.who.int/health-topics/coronavirus/. Accessed 30 April 2021.
2. Worldometer. COVID-19: Coronavirus Pandemic. Available: https://www.worldometers.info/coronavirus/. Accessed 30 April 2021.
3. Centers for Disease Control and Prevention. Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing. Available: https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html. Accessed 30 April 2021.
4. Yadav BK, Bihari C. Critical role of biobanks in COVID-19 pandemic. Indian Journal of Experimental Biology. 2021;59:7-10.
5. Allocca CM, Snapes E, Albert M, Bledsoe MJ, Castelhano MG, De Wilde M, et al. Biobanking in the COVID-19 era and beyond: Part 2. A set of tool Implementation case studies. BioPreservation and Biobanking. 2020;18(6):547-560.
6. Lankes HA, Makhlouf H. Biospecimen Collection During the COVID-19 Pandemic Considerations for Biobanking. American Journal of Clinical Pathology. 2021;155:55-63.
7. World Health Organization. 2020. Novel coronavirus (2019-nCoV) technical guidance: laboratory testing for 2019-nCoV in humans. World Health Organization, Geneva, Switzerland. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance. Accessed 26 March 2021.
8. GOV.UK (Online). Guidance COVID-19: a safe handling and processing for samples in laboratories. Available: https://www.gov.uk/government/publications/wuhan-novel-coronavirus-guidance-for-clinical-diagnostic-laboratories/wuhan-novel-coronavirus-handling-and-processing-of-laboratory-specimens. Accessed 9 September 2020
9. Cloudlims, 2020. COVID-19 Clinical data Management using LIMS. Available: https://www.cloudlims.com/blog/covid-19-clinical-data-management-using-lims-html. Accessed 10 September 2020.
10. Loibner M, Langner C, Regitnig P, Gorkiewicz G. Biosafety Requirements for Autopsies of Patients with COVID-19: Example of a BSL-3 Autopsy Facility Designed for Highly Pathogenic Agents. Pathobiology. 2021;88:37–45.
11. Vaught J. Biobanking During the COVID-19 Pandemic. BioPreservation and Biobanking. 2020;18(3):153-154. https://doi.org/10.1089/bio.2020.29069.jjv.
12. Peeling RW, Boeras D, Wilder-Smith A, Sall A, Nkengasong J. Need for sustainable biobanking networks for COVID-19 and other diseases of epidemic potential. Lancet Infectious Diseases. 2020.
13. Centers for Disease Control and Prevention. Vaccines for COVID-19. Available: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html. Accessed 30 April 2021.
14. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009; 6(7):e1000097.
15. Allocca C, Bledsoe MJ, Albert M, Anisimov SV, Bravo E, Castelhano MG, et al. Biobanking in the COVID-19 Era and Beyond: Part 1. How Early Experiences Can Translate into Actionable Wisdom. BioPreservation and Biobanking. 2020;18(6):533-546.
16. Tumilasci V, Nowacki PM, Puchois P. The Promise and Plight of Biobanking Initiatives during COVID-19 pandemic: The Urgent Need to Change Existing Practices. Trans-Hit Biomarkers Whitepaper - May 8, 2020; pp.1-5.
17. Simeon-Dubach D, Henderson MK. Opportunities and Risks for Research Biobanks in the COVID-19 Era and Beyond. BioPreservation and Biobanking. 2020;18(6):506-510.
18. Christoffels A, Abayomi A. Careful governance of African biobanks. Lancet. 2020; 395(10217):29-30.
19. Parichehreh-Dizaji S, Haghpanah V. Biosafety Guidelines for COVID-19 Specimens in Biobanks. BioPreservation and Biobanking. 2020;16(6): 587-591.
20. Hofman P, Puchois P, Brest P, Lahlou H, Simeon-Dubach D. Possible consequences of the COVID-19 pandemic on the use of biospecimens from cancer biobanks for research in academia and bioindustry. Nature Medicine. 2020;26(6):809-810.
21. Cannovo N, Cingolani M, Guarino R, Fedeli P. Regulation of Biobanks in Italy. Frontiers in Pediatrics. 2020;415(8):1-5.
22. Balcom D, Wolf L, Carrico RM, Marimuthu S, Al Haddad B, Malik DA. Implementation of the University of Louisville COVID-19 Biorepository: experiences from the Center of Excellence in Infectious Diseases (CERID). University of Louisville Journal of Respiratory Infections. 2020;4:1-12.
22. Food and Agricultural Organization. 2. Standard Operating Procedures. Available: http://www.fao.org/3/w7295e/w7295e04.htm. Accessed 26 March 2021.
23. IMFBlog. COVID-19: Without Help, Low-Income Developing Countries Risk a Lost Decade. Available: https://blogs.imf.org/2020/08/27/covid-19-without-help-low-income-developing-countries-risk-a-lost-decade/. Accessed 26 March 2021.
24. de Vries J, Huijsman R. Supply chain management in health services: An overview. Supply Chain Management. 2011;16(3):159-165.
25. GAO. COVID-19: Urgent Actions Needed to Better Ensure an Effective Federal Response- Report to Congressional Committees. Available: https://files.gao.gov/reports/GAO-21-191/index.html. Accessed 30 April 2021.
26. CSCMPs Supply Chain [Quarterly]. Strategy: COVID-19 and the health care supply chain: impacts and lessons learned. Available: https://www.supplychainquarterly.com/articles/4417-covid-19-and-the-health-care-supply-chain-impacts-and-lessons-learned. Accessed 30 April 2021.
27. Miller FA, Young SB, Dobrow M, Shojania KG. Vulnerability of the medical product supply chain: the wake-up call of COVID-19. BMJ Quality & Safety. 2020;3(4).
28. Yang J-R, Liu M-T, Huang H-I, Teng H-J, Chen J-H, Li S-Y. Building the national SARS-Cov-2 Laboratory diagnostic capacity in Taiwan. Health Security. 2020;18(5). https://doi.org/ 10.1089/hs.2020.0056 [Online ahead of print].
29. Biobanking. Safety for Biobanks: Strategies for Safe COVID-19 Specimens Handling. Published 25 April 2020. Available: https://www.biobanking.com/safety-for-biobanks-strategies-for-safe-covid-19-specimens-handling/. Accessed 10 September 2020.